Beijing Shenogen Pharmaceutical Co.,Ltd (Shenogen Pharm) Signed a Strategic Cooperation Agreement in Cancer Immunotherapeutics with the Institute of Materia Medica (IMM) at Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC)

Beijing Shenogen Pharmaceutical Co.,Ltd (Shenogen Pharm) signed a strategic cooperation agreement with the Institute of Materia Medica (IMM) at Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC) during the 19th Beijing Pharmaceutical Congress (BPC 2017) that was held on December 23, 2017 at the Beijing International Conference Center. This collaboration laid the foundation for the industry-academic partnership between the two parties, which will lead to a strong alliance in accelerating the translation of drug research and development achievements into innovative medicine for cancer immunotherapy, and also provide Shenogen Pharm with more effective combination immunotherapy programs for the anticancer agents in pipelines.

About the Institute of Materia Medica (IMM) at Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC)：

The Institute of Materia Medica (IMM) at Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC) is one of the national key research institutes. IMM continuously focuses on drug discovery and research to prevent common diseases, frequently occurring diseases and complex diseases that seriously compromise human health. By emphasizing the development of innovative drugs that hold independent intellectual property rights and applying modern medicinal theories and technologies to conduct multidisciplinary research, IMM is dedicated to finding special new drug development pathways with Chinese characteristics. The main research directions of IMM include anticancer drugs, drugs for the prevention and treatment of cardiovascular and cerebrovascular diseases, drugs for the treatment of neuropsychiatric diseases, drugs for anti-metabolic disorders, anti-infectives, anti-inflammatory immune drugs, and drugs for the treatment of age-related degenerative diseases。

About Shenogen Pharmaceutical Co.,Ltd：

Beijing Shenogen Pharmaceutical Co.,Ltd is a high-tech drug discovery and development enterprise that holds international leading and cutting-edge technologies. The company possesses a robust professional R&D team and the exclusive global patent for a novel membrane-bound ER-alpha 36 drug target. The company is dedicated to the research and development of the world’s first new anti-cancer drugs. The company’s original natural small molecule immunotherapy Class I new drug Icaritin has started in Phase III clinical trial，and gained support from both the National "Twelve Five" and "Thirteen Five" programs for major new drug development. The company currently has product pipelines spanning from small molecules，oncolytic virus to anti-PD-L1immune checkpoint inhibitor, which facilitates the company with multiple combination medications in the field of cancer immune combination therapy, and ultimately benefit cancer patients in China.